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A Bayesian-derived 24-hour area under the concentration-time curve over minimum 
inhibitory concentration from broth microdilution (AUC24h/MICBMD) ratio of 400 to 600 is 
recommended as the new monitoring parameter for vancomycin to optimize efficacy and 
minimize nephrotoxicity.  The AUC24h threshold of 600 mg*h/L for nephrotoxicity was 
extrapolated from studies that assessed the general population.  It is unclear if this upper 
threshold is consistent or varies when used in special populations such as critically ill patients, 
obese patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins. 
The purpose of this study is to investigate the generalizability of the proposed 
vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity.  The objective is to determine 
the optimal Bayesian-derived AUC24h threshold to minimize vancomycin-associated 
nephrotoxicity in special populations such as critically ill patients, obese patients, patients with 
preexisting renal disease, and patients on concomitant loop diuretics, ACEIs, ARBs, NSAIDs, 
aminoglycosides, piperacillin-tazobactam, and IV contrast dyes. 
The study design is a single-center, retrospective cohort study.  For each patient, 
nephrotoxicity was assessed and the Bayesian-derived AUC24h was estimated.  Using 
classification and regression tree (CART) analysis, the AUC24h threshold for nephrotoxicity was 
determined for each special population that had at least ten nephrotoxic patients.  The predictive 
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performances (e.g., positive predictive value [PPV], negative predictive value [NPV], sensitivity, 
specificity, and area under the receiver operating characteristic [ROC] curve) of each CART-
derived threshold were then compared to the guideline threshold’s predictive performances.  
PPV and sensitivity were given greater weight when comparing the thresholds.  
Of the 336 patients, 29 (8.6%) nephrotoxic patients were observed after  initiating 
vancomycin.  Among the special populations of interest, critically ill patients, obese patients, 
patients with preexisting renal disease, and patients on concomitant loop diuretics included at 
least ten nephrotoxic patients and thus were further analyzed to determine the CART-derived 
AUC24h thresholds.  The CART-derived AUC24h thresholds were 544 mg*h/L for critically ill 
patients (n=116), 586 mg*h/L for obese patients (n=111), 539 mg*h/L for patients with 
preexisting renal disease (n=54), and 543 mg*h/L for patients on concomitant loop diuretics 
(n=126).  Compared to the guideline threshold of 600 mg*h/L, the CART-derived thresholds for 
critically ill patients, patients with preexisting renal disease, and patients on concomitant loop 
diuretics had comparable PPVs but significantly higher sensitivities.  On the other hand, the 
CART-derived threshold for obese patients did not have a significantly different PPV, NPV, 
sensitivity, specificity, and area under the ROC curve.  
For critically ill patients, patients with preexisting renal disease, and patients on 
concomitant loop diuretics, a lower vancomycin AUC24h threshold for nephrotoxicity such as 
544 mg*h/L, 539 mg*h/L, and 543 mg*h/L, respectively, may be considered to minimize the 
risk of nephrotoxicity.  On the other hand, this study supports the continued use of the guideline 
threshold of 600 mg*h/L to minimize the risk of nephrotoxicity in obese patients.  
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 Vancomycin is a bactericidal glycopeptide antibiotic that remains a mainstay of treatment 
for methicillin-resistant Staphylococcus aureus (MRSA) and other severe gram-positive 
infections.1,2  When given intravenously, vancomycin demonstrates characteristics of a dose-
response and dose-toxicity relationship with a narrow therapeutic index which warrants careful 
dosing and monitoring of the antibiotic.  
 Previously published vancomycin therapeutic monitoring consensus guidelines 
recommended trough concentrations as a surrogate marker for the 24-hour area under the 
concentration-time curve over minimum inhibitory concentration (AUC24h/MIC) ratio due to a 
history of difficulty in obtaining multiple vancomycin concentrations and subsequently 
calculating the area under the concentration-time curve over 24 hours (AUC24h).1  However, an 
enhanced method of using Bayesian software programs has been shown to generate accurate and 
reliable estimates of the AUC24h.  Additionally, studies have shown a high degree of 
interindividual variability between a trough concentration and its respective AUC24h.9  A 
simulation of 5,000 vancomycin concentration versus time profiles derived from administering  
1,000 milligrams every eight hours examined the relationship between trough concentrations and 
AUC24h values.3  In the study, trough concentrations correlated with less than 50% of the AUC24h 
values (R2=0.409).  Trough concentrations are suspected to be poor surrogate markers for 
AUC24h values as a trough concentration is a single exposure point after a dose is administered 
while the AUC24h represents the cumulative drug exposure over 24 hours.  Furthermore, no link 
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between treatment success and vancomycin trough concentrations was demonstrated throughout 
the entire trough continuum.3  
On the other hand, with high vancomycin concentration targets, specifically 15 to 20 
mg/L, there is a considerable concern for unnecessarily high AUC24h values that can put patients 
at an increased risk of vancomycin-associated nephrotoxicity.4  Compared to trough-based 
monitoring, studies have shown that AUC24h-based monitoring significantly decreased the 
incidence of vancomycin-associated nephrotoxicity.5,6  In a retrospective, quasi-experimental 
study, Finch et al. assessed 546 patients dosed using trough concentrations versus 734 patients 
dosed using AUC24h.6  They determined that AUC24h-based monitoring was associated with a 
significantly lower incidence of vancomycin-associated nephrotoxicity (OR, 0.52; 95% CI, 0.34-
0.80; p=0.003).  Cox proportional hazards regression also revealed similar results (hazard ratio 
[HR], 0.53; 95% CI, 0.35-0.78; p=0.002).  Moreover, Neely et al. conducted a prospective 
observational study consisting of 252 patients and compared trough-based monitoring in the first 
year versus AUC24h-based monitoring  in the second and third year.7  Nephrotoxicity occurred in 
8% of the patients in the first year and occurred in 0% and 2% of the patients in the second and 
third year, respectively.  Compared to AUC24h-based monitoring, trough-based monitoring had 
significantly higher rates of trough concentrations greater than 15 mg/L (p<0.001) and 
vancomycin-associated nephrotoxicity (p=0.01).  
Over the past decade, trough-based monitoring for vancomycin has been well integrated 
into practice despite limited evidence on the clinical benefits of maintaining trough 
concentrations between 15 to 20 mg/L for serious MRSA infections.  However, in March 2020, 
the American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of 
America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious 
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Diseases Pharmacists (SIDP) published an updated vancomycin therapeutic monitoring 
consensus guideline that recommends AUC24h-based monitoring over trough-based monitoring 
for patients with suspected or definitive serious MRSA infections.4  Due to the guideline’s 
updated recommendation, more clinicians and hospital institutions are in the midst of 
transitioning or expected to transition to AUC24h-based monitoring for vancomycin. 
Introduction to Research 
The 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring guideline no longer 
recommends trough-based monitoring with a target of 15 to 20 mg/L for patients with serious 
MRSA infections.4  Additionally, it recommends a Bayesian-derived AUC24h/MIC from broth 
microdilution (AUC24h/MICBMD) ratio of 400 to 600, as the new optimal pharmacokinetics (PK) 
and pharmacodynamics (PD) target for vancomycin.  Rybak et al. concluded that AUC24h-based 
monitoring using an AUC24h/MICBMD ratio of 400 to 600 optimizes clinical efficacy and 
minimizes nephrotoxicity risk in patients with serious MRSA infections such as bacteremia, 
pneumonia, and osteomyelitis. 
The vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity was primarily 
extrapolated from studies that assessed the general population.4,8-12  They demonstrated that 
AUC24h values greater than thresholds ranging from 550 to 800 mg*h/L were significantly 
associated with an increased likelihood of nephrotoxicity.1-6  It is unclear if this upper threshold 
is consistent or varies when used in special populations such as critically ill patients, obese 
patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins.4  ICU 
patients and obese patients were shown to be associated with a significantly higher risk of 
vancomycin-associated nephrotoxicity.9,13-16  Preexisting renal disease and concomitant 
nephrotoxins were also shown to play a synergistic role with vancomycin in increasing the risk 
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of vancomycin-associated nephrotoxicity.17-20  However, literature assessing the vancomycin 
AUC24h threshold for nephrotoxicity in the aforementioned special populations is limited and 
warrants further investigation. 
Definition of Terms 






Key Terms and Definitions 
Term Definition 
AUC24h 
The area under the concentration-time curve over 24 hours 
which represents the cumulative drug exposure over 24 hours. 
MIC 
The lowest concentration of an antibiotic that completely 
inhibits the growth of a microorganism in vitro.   
AUC24h/MIC 
The 24-hour area under the concentration-time curve over MIC 
ratio.  
Peak Concentration  
The highest serum concentration reached by a drug following 
an administered dose.  
Trough Concentration 
The lowest serum concentration reached by a drug before the 
next dose is administered.  
Steady State 
The state when the rate of drug intake equals its rate of 
elimination. 
Bayesian PK 
The prediction of PK parameters and dosing regimens by 
integrating information gathered from population PK and the 
patient’s measured drug levels. 
CART Analysis 
The use of classification to create a predictive model that 
predicts the value of an outcome or dependent variable using 
known values of explanatory variables.  
CART-Derived Threshold 
Used in this study to refer to the vancomycin AUC24h threshold 
for nephrotoxicity that was derived from this study’s CART 
analysis. 
Guideline Threshold 
Used in this study to refer to the vancomycin AUC24h threshold 
of 600 mg*h/L for nephrotoxicity recommended by the 2020 
ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring 
guideline. 
PPV 
The probability of patients with a positive screening test truly 
having the condition. 
NPV 
The probability of patients with a negative screening test truly 
not having the condition.  
Sensitivity 
The proportion of patients with a condition who are correctly 
identified by a screening test as truly having that condition. 
Specificity 
The proportion of patients without a condition who are 
correctly identified by a screening test as truly not having that 
condition. 
Area under the ROC Curve 
A combined measure of sensitivity and specificity which 
numerically provides the overall predictive performance of a 
screening test or diagnostic test. 
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; MIC, minimum 
inhibitory concentration; AUC24h/MIC, 24-hour area under the concentration-time curve over the 
minimum inhibitory concentration ratio; PK, pharmacokinetics; CART, classification and 
regression tree; PPV, positive predictive value; NPV, negative predictive value; ROC, receiver 
operating characteristic.  
17 
 
Purpose and Objectives 
The purpose of this study is to investigate the generalizability of the proposed 
vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity.  The primary objective is to 
determine the optimal Bayesian-derived AUC24h threshold to minimize vancomycin-associated 
nephrotoxicity in special populations such as intensive care unit (ICU) or critically ill patients 
and obese patients.  In addition, this study investigated the optimal Bayesian-derived AUC24h 
threshold for nephrotoxicity in patients with preexisting renal disease and patients on 
concomitant nephrotoxins other than vancomycin. 
Research Questions 
1. For each special population, what is the CART-derived AUC24h threshold for vancomycin-
associated nephrotoxicity?  
 
a. ICU or Critically Ill Patients 
b. Obese Patients 
c. Patients with Preexisting Renal Disease 
d. Patients on Concomitant Nephrotoxins 
i. Loop diuretics 
ii. Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor 
Blockers (ARBs)  
 
iii. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
iv. Aminoglycosides 
v. Piperacillin-Tazobactam  
vi. Intravenous (IV) Contrast Dyes 
2. For each special population, how do the predictive performances (i.e., positive predictive 
value [PPV], negative predictive value [NPV], sensitivity, specificity, and area under the 




a. ICU or Critically Ill Patients 
b. Obese Patients 
c. Patients with Preexisting Renal Disease 
d. Patients on Concomitant Nephrotoxins 
i. Loop diuretics 
ii. ACEIs or ARBs 
iii. NSAIDs 
iv. Aminoglycosides 
v. Piperacillin-Tazobactam  




CHAPTER 2: REVIEW OF THE LITERATURE 
 
Methods to Estimate Vancomycin AUC24h 
 In a retrospective observational study, vancomycin’s efficacy and safety were shown to 
be more closely related to AUC24h and AUC24h/MIC ratio versus trough concentrations.21  Given 
vancomycin’s narrow range to optimize efficacy and minimize nephrotoxicity, an accurate 
method of calculating the AUC24h is needed.4  Until recently, the traditional method of using 
multiple PK samples and the linear-trapezoidal formula was used to calculate AUC24h.  However, 
the practical difficulties of this method for vancomycin monitoring are why trough 
concentrations were originally used as surrogate markers for AUC24h.4  Pai et al. proposed two 
simplified approaches that were shown to have a high precision and low bias despite only using 
one to two vancomycin concentrations.3  
 The first approach relies on Bayesian software programs, population modeling, and one 
or more vancomycin concentrations to estimate the AUC24h.3  By using a Bayesian approach, 
probabilities defined as the Bayesian priori and Bayesian posteriori are predicted.22  The 
Bayesian priori uses a population PK model and identifies demographic, pathophysiological, 
environmental, and drug-related factors that can impact vancomycin’s disposition.   
Vancomycin’s PK parameters and AUC24h are estimated for each patient by predicting how 
vancomycin will behave based on prior knowledge about the parameters of interest from 
previous patient population data.  Contrastingly, the Bayesian posteriori involves using patient-
specific information such as trough concentrations and peak concentrations to revise or update 
the estimations of the PK parameters of interest and AUC24h.22  The Bayesian method is shown 
to be as accurate as the traditional first-order PK method of using the linear-log trapezoidal 
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rule.23  Using a dataset derived from 19 ICU patients, Turner et al. compared the AUC values 
estimated by multiple Bayesian dose-optimizing software programs to the AUC values 
calculated using the linear-log trapezoidal rule (AUCREF).  The study obtained vancomycin 
serum levels during the vancomycin infusion, at the end of the infusion, at 60, 120 and 300 
minutes after the infusion, and immediately before the next dose of vancomycin.  In the study, 
accuracy was defined as the median ratio of the estimated AUC to AUCREF and bias was defined 
as the median of the absolute value of the percentage difference between the estimated AUC 
from AUCREF [(|AUC – AUCREF|/AUCREF) x 100].  With one to two vancomycin concentrations, 
the Bayesian method produced average accuracy ratios of 0.80 or higher and a bias of less than 
20% which are expected to be adequate when targeting an AUC24h of 400 to 600 mg*h/L.23  
 The second approach proposed by Pai et al. uses first-order PK equations and two steady 
state vancomycin concentrations that are obtained during the same dosing interval.3  With this 
method, a trough concentration and peak concentration are obtained to create a simple mono-
exponential curve.  The snapshot of the patient’s vancomycin dosing regimen is then used, along 
with first-order PK equations, to calculate the AUC24h.  With a dataset of 47 intensively sampled 
adults who received vancomycin, Pai et al. used a Bayesian-derived AUC24h from all 
vancomycin samples inputted as a reference to assess the accuracy of the second approach which 
only used two vancomycin samples.  Their results showed that the simplified equation-based 
approach tends to underpredict or overpredict the AUC24h by 2% or less which they deemed as 
clinically insignificant.9  
Despite having a similar accuracy as the Bayesian method, the second approach has a 
major downfall of only being able to provide a static estimation of the AUC24h during the 
specific time period when the concentration levels were collected.23  Therefore, the second 
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approach must be used at steady state and does not account for continuing acute physiologic 
changes such as renal impairment that can occur during or after the collecting period.  Slight lab 
errors during the collecting period of the two samples can also make a considerable impact on 
the estimation of the PK values.  For example, a vancomycin concentration that is collected too 
early may still be in the alpha phase and lead to erroneous estimates of the rate of elimination for 
the simple mono-exponential curve.  Contrastingly, the Bayesian method can use vancomycin 
concentrations obtained at any time.  It can estimate the AUC24h at steady state despite the 
sample being drawn before steady state.  This is especially advantageous for patients who are 
limited on being able to achieve steady state such as critically ill patients.  Another downfall to 
using first-order PK equations is that it creates a simple mono-exponential curve rather than 
capturing vancomycin’s two-compartment distribution and elimination.23  On the other hand, the 
Bayesian method allows for application of multiple PK models including a two-compartment 
model.  It can also be modified to be an adaptive program that can account for different dosing 
patterns such as when loading doses are given or when covariates such as creatinine clearance 
are unstable.3 
Therefore, this study followed the first approach proposed by Pai et al. to estimate the 
AUC24h values.3  The Bayesian software program used in this study was PrecisePK (Version 
20.02.00, Healthware Inc., San Diego, CA) and one or more trough concentrations were used to 
calculate the Bayesian posteriori. 
AUC24h/MIC Threshold for Vancomycin’s Efficacy 
The broth microdilution (BMD) method and Etest are the two most common methods to 
estimate the minimum inhibitory concentration (MIC) of staphylococci.  The Etest generally 
predicts the MIC to be 1.5- to 2-fold higher than the MIC calculated using the BMD method after 
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log conversion.24  An AUC24h/MICBMD ratio of 400 to 600 approximately corresponds to an 
AUC24h/MICEtest ratio of 200 to 400.  For vancomycin dosing in nonserious infections, the 
variability between the methods to estimate the MIC can be insignificant.  However, the 
standardization and confirmation of the MIC method is imperative for patients with serious 
MRSA infections who require prompt achievement of the target AUC24h/MIC ratio.  Therefore, 
the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring guideline recommends using 
the BMD method to estimate the MIC as most AUC24h/MIC ratio data were generated using 
MICBMD.4  Currently, an AUC24h/MICBMD ratio greater than or equal to 400 is recommended as 
the optimal PK target for vancomycin’s efficacy for serious MRSA infections. 
The AUC24h/MICBMD ratio of greater than or equal to 400 is supported by in vitro and in 
vivo research on the PK and PD of vancomycin.4,25  Animal model studies demonstrated a 1- to 
2-log reduction in bacterial inoculum when the vancomycin AUC24h/MICBMD ratio is greater than 
400.4  Additionally, in vitro data on two strains of methicillin-susceptible Staphylococcus aureus 
(MSSA) and MRSA showed that an AUC24h/MICBMD ratio less than 400 increases vancomycin 
resistance and the development of vancomycin-intermediate Staphylococcus aureus strains.  The 
vancomycin MIC of both strains increased from 1 mg/L to 4 mg/L within 144 hours of 
subtherapeutic vancomycin exposure.25 
Initially, studies on the relationship between AUC/MIC ratio and the clinical efficacy of 
vancomycin were small-scale retrospective studies that used a formula-based approach to 
estimate the AUC values.2,4,12,26-28  Moise et al. retrospectively evaluated patients with hospital-
acquired pneumonia due to MSSA or MRSA.28  Based on 70 patients, Moise-Broder et al. 
determined that there was a significantly higher clinical success rate in patients with 
AUC24h/MICBMD ratios greater than or equal to 350 (odds ratio [OR], 7.19; 95% CI, 1.91-27.3; 
23 
 
p=0.0036).  Additionally, the median duration for bacteriological eradication of MSSA and 
MRSA was significantly shorter for patients with AUC24h/MICBMD ratios greater than or equal to 
350 (10 days vs. excess of 30 days; p=0.0402).28  Similar methods were done on studies 
evaluating patients with MRSA bacteremia.2,26,27  Kullar et al. conducted a retrospective cohort 
study of 320 adults with MRSA bacteremia and identified an AUC24h/MICBMD threshold of 421 
using a classification and regression tree (CART) analysis.2  Patients with AUC24h/MICBMD 
ratios less than 421 had a significantly higher rate of treatment failure (61.2% vs. 48.6%; 
p=0.038).  Likewise, Holmes et al. and Jung et al. assessed patients with MRSA bacteremia and 
reported similar AUC24h/MICBMD thresholds.26,27  Holmes et al. followed a multicenter 
observational cohort of 182 adults.  Patients who achieved an AUC24h/MICBMD ratio greater than 
373 had a significantly lower rate of 30-day mortality (71.6% vs. 84.3%; p=0.043).27  Jung et al. 
assessed 76 patients with MRSA bacteremia and determined that an AUC24h/MICBMD ratio less 
than 398.5 was associated with a higher rate of treatment failure (45.0% vs. 23.2%; p=0.065).26   
In a retrospective cohort study of 44 patients with MRSA bacteremia, Mogle et al. used the 
trapezoidal rule and two-point PK approach to estimate AUC24h.12  Patients with 
AUC24h/MICBMD ratios greater than or equal to 297 had a greater than 2.7-fold increase in 
clinical success (94.4% vs. 50.0%; p=0.01).  
Instead of using the formula-based approach, recent studies used the Bayesian method to 
estimate the AUC values.21,29  In a retrospective study of 123 cases of MRSA bacteremia, Lodise 
et al. determined that treatment failure significantly decreased when day 1 AUC0-24h/MICBMD 
ratios were greater than 521 (relative risk [RR], 0.54; 95% CI, 0.32-0.91; p=0.02).  Patients with 
AUC24-48h/MICBMD  ratios greater than 650 on day 2 also had a significant reduction in treatment 
failure (RR, 0.58; 95% CI, 0.34-0.99; p=0.05).21  Casapao et al. evaluated 139 patients with 
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definite or possible MRSA infective endocarditis.  Even after adjusting for factors such as 
presence of heterogenous vancomycin-intermediate Staphylococcus aureus, ICU admission, IV 
drug use, previous hospitalization, and age, they determined that treatment failure remained 
significantly higher for patients with AUC0-24h/MICBMD ratios less than or equal to 600 (aOR, 
2.331; 95% CI, 1.012-5.371; p=0.047).29 
Two studies used a similar Bayesian approach to estimate AUC24h but only used MICEtest 
to calculate the AUC24h/MIC ratio.30,31  Brown et al. included 18 patients with infected 
endocarditis and 32 patients with complicated bacteremia (e.g., patients with two positive blood 
cultures and metastatic foci of the infection).30  They determined that patients who had 
AUC24h/MICEtest ratios less than 211 had a greater than 4-fold increase in death (38% vs. 8%; 
p=0.02).  On the other hand, Garwonoski et al. evaluated 59 patients who had MRSA bacteremia 
and osteomyelitis.31  Patients with AUC24h/MICEtest ratios greater than 293 were associated with a 
2.5-fold decrease in time to microbiological clearance (4 ± 2 days vs. 6 ± 3 days; p=0.01).  Due 
to the MICEtest usually being 1.5- to 2-fold higher than the MICBMD, the AUC24h/MICEtest  
thresholds are suspected to align with the AUC24h/MICBMD thresholds determined by previous 
studies.21,29-31 
The extrapolation of using an AUC/MICBMD ratio of 400 to 600 is limited because it is 
primarily based on retrospective, single-center analyses.  Therefore, Lodise et al. conducted a 
prospective, multicenter study that assessed the relationship between AUC/MIC ratios on day 2 
and clinical outcomes in 265 adult patients with MRSA bacteremia.32  No AUC/MICBMD 
threshold for vancomycin’s clinical efficacy was identified due to only 20% of the study 
population having AUC/MICBMD ratios less than 400 mg*h/L.  They recommended to continue 
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maintaining an AUC/MICBMD ratios greater than 400 mg*h/L as it remains unclear if 
vancomycin’s clinical efficacy is maintained below that threshold. 
The vancomycin AUC24h/MICBMD target is primarily derived from patients with 
Staphylococcus aureus bacteremia, pneumonia, osteomyelitis, and endocarditis.4  Hence, 
research on the AUC24h/MICBMD threshold in other MRSA-associated infections such as skin and 
soft tissue infections (SSTI), necrotizing fasciitis, infected hardware, and septic joints and in 
vancomycin special populations such as amphetamine users, IV drug users (IVDU), critically ill 
patients, and patients on concomitant immunosuppressants is warranted.  The current study 
initially included the objective of assessing the aforementioned MRSA-associated infections and 
vancomycin special populations and their AUC24h/MICBMD thresholds for clinical efficacy.   
However, the study was unable to accomplish this objective due to limitations explained in 
Chapter 5. 
AUC24h Threshold for Vancomycin-Associated Nephrotoxicity 
 An AUC24h of 600 mg*h/L is currently recommended as the upper threshold for 
vancomycin to minimize the risk of nephrotoxicity.4  The threshold was based on collective 
literature that showed the risk of vancomycin-associated nephrotoxicity increases along the AUC  
continuum and is at its highest when AUC24h is greater than 550 to 800 mg*h/L.  
In a retrospective study of 31 patients, Suzuki et al. compared the highest Bayesian-
derived AUC24h values during the treatment period versus the occurrence of nephrotoxicity.8  A 
majority of the patients who did not develop nephrotoxicity had AUC24h values between 400 to 
600 mg*h/L while most patients who experienced nephrotoxicity had AUC24h values between 
600 to 800 mg*h/L (p=0.014).  Allen et al. conducted a retrospective cohort study of 278 
patients.32  They compared the incidence of nephrotoxicity between patients with AUC0-24h 
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values less than 700 mg*h/L and patients with AUC0-24h values greater than 700 mg*h/L.33   
Patients above the prespecified threshold had a significantly higher incidence of nephrotoxicity 
(24.5% vs. 13.1%; p=0.021).  
Moreover, studies identified CART-derived vancomycin AUC thresholds for 
nephrotoxicity and suggested that the risk of nephrotoxicity increases in relation to AUC24h.33-36   
Lodise et al. assessed 166 patients and calculated AUC0-24h using a Bayesian method.33  They 
observed that an AUC0-24h greater than or equal to 1,300 mg*h/L increased the risk of 
vancomycin-associated nephrotoxicity (25.9% vs. 10.1%; p=0.05).  Zasowski reported similar 
findings in a multicenter, retrospective study of 323 patients.34  The incidence of nephrotoxicity 
significantly increased when AUC0-24h was greater than or equal to 677 mg*h/L, AUC24-48h was 
greater than or equal to 683 mg*h/L, and AUC0-48h was greater than or equal to 1218 mg*h/L.  In 
a retrospective study of 127 patients, Chavada et al. also demonstrated a similar relationship 
between AUC0-24h and vancomycin-associated nephrotoxicity.35  Patients with AUC0-24h values 
greater than the CART-derived threshold of 565 mg*h/L had a significantly greater risk of 
nephrotoxicity (40% vs. 11.2%; p=0.002).  Furthermore, Chavada et al. observed that the risk of 
nephrotoxicity increased by 0.2% as AUC0-24h increased by 1 mg*hr/L (OR, 1.002; 95% CI, 
1.001-1.004; p=0.021).  Lastly, Lodise et al. conducted a multicenter, prospective observational 
study of 265 adults with MRSA bacteremia and determined that the risk of AKI continually 
increased as AUC24-48h increased.  In their study, patients with AUC24-48h values greater than or 
equal to 793 mg*h/L had the highest risk of AKI (RR, 0.16; 95% CI, 0.04-0.29).36   
Aljefri et al. conducted a meta-analysis on randomized case-control and cohort studies 
that reported AUC values and the incidence of nephrotoxicity.10  Including the aforementioned 
studies, the meta-analysis consisted of six retrospective studies and two prospective studies.  The 
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studies estimated AUC using a Bayesian approach with the exception of the study by Finch et al. 
Because the studies reported multiple AUC values (e.g., AUC0-24h and AUC24-48h) that ranged 
from 550 to 700 mg*h/L, an endpoint of 650 mg*h/L was used to define low versus high AUC 
values.  Patients with low AUC0-24h values had a significantly lower risk of AKI than those with 
high AUC0-24h values (OR, 0.36; 95% CI, 0.23-0.56; p<0.001).  Patients with low AUC24-48h 
values also had similar results (OR, 0.68; 95% CI, 0.46-0.99; p=0.002).4  Similarly, Mogle et al. 
identified a CART-derived AUC24h threshold of 710 mg*h/L.12  Patients with AUC24h values 
greater than or equal to 710 mg*h/L within the first 96 hours of vancomycin had a higher rate of 
nephrotoxicity (33.3% vs. 2.5%; p=0.04). 
The aforementioned studies defined vancomycin-associated nephrotoxicity as an increase 
in serum creatinine (SCr) by greater than or equal to 0.5 mg/dL or a 50% increase from baseline 
on two or more consecutive measures.8,12,32-36  However, this study defined vancomycin-
associated nephrotoxicity as an increase in SCr by 0.3 mg/dL or more within 48 hours while on 
vancomycin or an increase in SCr by 1.5 times the baseline which is known or presumed to have 
occurred within seven days of discontinuing vancomycin.37  A less stringent definition of 
vancomycin-associated nephrotoxicity was used to include more nephrotoxic patients.   
Additionally, studies did not examine the vancomycin AUC24h thresholds for nephrotoxicity in 
vancomycin special populations.8,12,32-36  Rather, they assessed the thresholds for the general 
population of patients who were on vancomycin.  More studies are needed to determine if the 
vancomycin AUC24h threshold for nephrotoxicity is altered in certain vancomycin special 
populations.  This is especially important for vancomycin special populations that are associated 
with an increased risk of vancomycin-associated nephrotoxicity such as the ones discussed in the 
next section.   
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Vancomycin PK and PD Changes in Special Populations 
 Studies on the use of vancomycin in special populations such as critically ill patients, 
obese patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins 
showed that the PK and PD of vancomycin can be altered as a result of physiological 
changes.13,17,18,20,24,38-40  Thus, these special populations can have an increased risk of adverse 
effects from vancomycin.  Host-related factors such as critical illness, increased weight, 
preexisting renal disease, and concomitant nephrotoxic agents have been associated with an 
increased risk of vancomycin-associated nephrotoxicity.14-16,33,41-43  However, there are currently 
no studies that investigate whether the AUC24h threshold for vancomycin-associated 
nephrotoxicity changes when used in the aforementioned special populations.4  Therefore, 
analyses on their vancomycin AUC24h thresholds for nephrotoxicity are warranted.  
Critically Ill or ICU Patients 
Critically ill patients require larger doses of vancomycin due to their high acuity and their 
offending pathogens being less susceptible.13  They also tend to have hemodynamic instability 
and renal hypoperfusion that can increase their risk of nephrotoxicity.  Furthermore, 
vancomycin’s altered volume of distribution (Vd) in critically ill patients increases the risk of 
nephrotoxicity.13,38  Critically ill patients with severe sepsis can experience fluid shifts from the 
intravascular compartment to the interstitial space due to excessive fluid resuscitation, 
widespread endothelial injury, and capillary leakages.13  This results in altering the PK of 
hydrophilic drugs like vancomycin by causing an increase in Vd and a decrease in plasma 
concentration.13,38  
Studies demonstrated that variables independently associated with vancomycin-
associated nephrotoxicity are ICU residence (aOR, 3.25; 95% CI, 1.18-9.98; p=0.02) and a high 
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Acute Physiology and Chronic Health Evaluation (APACHE) II score (22.9 ± 7.4 vs. 18.2 ± 8.5; 
p=0.006).16,33  In a retrospective study of 166 patients, Lodise et al. also showed that ICU 
patients have a greater than 20% probability of experiencing nephrotoxicity with initial trough 
concentrations greater than 10 mg/L.33 
Obese Patients 
Physiologic changes in obese patients have been shown to alter the Vd of vancomycin.39   
Obese patients have a higher Vd of vancomycin due to having higher levels of lean body mass 
and larger organs than patients of normal weight.40,44   Despite vancomycin being hydrophilic, 
high levels of adipose tissue are also suspected to play a role in increasing the Vd.  Due to water 
accounting for approximately 30% of the content of adipose tissues, vancomycin is able to 
distribute in the adipose tissue to a certain extent.39,40  Additionally, obese patients experience 
increased blood flow due to having a higher blood volume and cardiac output.40  In combination 
with vancomycin’s hydrophilic nature, their increased blood flow can contribute to a higher Vd.  
Currently, there are conflicting studies on the relationship between obesity and the risk of 
vancomycin-associated nephrotoxicity. 14,15,42,43,45  In a retrospective study of 207 obese patients 
with a body mass index (BMI) greater than 30 kg/m2 and 323 lean patients, obesity was not 
associated with an increased risk of nephrotoxicity (RR, 0.98; 95% CI, 0.93-1.04; p=0.59).45   
Contrastingly, there are multiple studies that suggest a relationship between obesity and an 
increased risk of vancomycin-associated nephrotoxicity.14,15,42,43  In a multicenter, retrospective 
study of 337 patients, weight greater than 100 kg was found to be an independent predictor of 
nephrotoxicity (OR, 2.74; 95% CI, 1.27-5.91).14  In a retrospective study of 270 veterans, Horey 
et al. also found weight to be significantly associated with an increased risk of nephrotoxicity 
(OR, 1.02; 95% CI, 1.00-1.03).15  Furthermore, Choi et al. demonstrated that obesity class III 
30 
 
(BMI ≥40 kg/m2) patients have a 3-fold greater risk of vancomycin-associated nephrotoxicity 
compared to obesity class I and II (BMI 30-39.9 kg/m2) patients and nonobese patients (OR, 
3.14; 95% CI, 1.27-7.75 and OR, 2.99; 95% CI, 1.12-7.94, respectively).42  These findings are 
consistent with results from a retrospective cohort study of 246 patients conducted by Lodise et 
al. which showed that patients who weigh greater than or equal to 101.4 kg were approximately 
3.5 times more likely to develop nephrotoxicity (HR, 3.65; 95% CI 2.52-5.28, p<0.001).43  A 
mechanistic explanation for obesity being associated with an increased risk of vancomycin-
associated nephrotoxicity remains unclear.  However, studies hypothesize that a likely factor is 
the large Vd that causes disproportionately larger doses of vancomycin and a more intensive 
vancomycin exposure profile.42,43    
Patients with Preexisting Renal Disease 
Patients with preexisting renal disease are at a higher risk of developing vancomycin-
associated nephrotoxicity.20  Vancomycin is primarily eliminated renally and its extrarenal 
clearance is approximately 5%.17  Vancomycin is predominantly cleared through glomerular 
filtration and through active tubular secretion to a certain degree.  With a decrease in renal 
function, the half-life of vancomycin increases linearly.  Thus, patients with preexisting renal 
disease have a higher risk of vancomycin accumulating.  Normally, the half-life of vancomycin 
is six hours.  However, in patients with anuria, the half-life can soar up to 100 to 200 hours.  As 
vancomycin accumulates, there is a higher risk of vancomycin overdosing and subsequent 
nephrotoxicity.  
Patients on Concomitant Nephrotoxins 
Vancomycin has been shown to decrease the threshold for nephrotoxicity and has 
demonstrated synergistic activity with other nephrotoxins administered concomitantly.18,20  
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Studies demonstrated that the coadministration of nephrotoxins such as loop diuretics, renin‐
angiotensin system blockers, NSAIDs, aminoglycosides, piperacillin-tazobactam, and IV 
contrast dyes increases the risk of renal toxicity.18,46-50  In a prospective cohort study of 95 
patients, Hidayat et al. determined that patients on concomitant nephrotoxins were significantly 
associated with an increased risk of nephrotoxicity (91% vs. 20%; p<0.001).19  Even after 
performing a multivariate analysis and controlling other significant factors such as age, 
APACHE II score, admission to ICU, vancomycin trough concentrations, and duration of 
vancomycin therapy, coadministration of nephrotoxins remained the most significant predictor of 
nephrotoxicity occurrence (p=0.003).  
Matson et al. demonstrated that the concomitant use of loop diuretics, ACEIs, and  
NSAIDs increases the risk of vancomycin-associated nephrotoxicity by 43-fold, 5-fold, and 19-
fold, respectively.18  For aminoglycosides, Rybak et al. assessed 224 patients who received 
vancomycin alone, gentamicin alone, or vancomycin plus an aminoglycoside.47  Patients who 
received both vancomycin and an aminoglycoside had a significantly higher rate of 
nephrotoxicity than patients who received vancomycin or gentamicin alone (22% vs. 5% vs. 
11%, respectively; p<0.05).  Similarly, Hanrahan et al. assessed 158 critically ill patients and 
demonstrated that concomitant aminoglycosides with vancomycin increased the occurrence of 
nephrotoxicity (OR, 18.9; p=0.002).48  
Although piperacillin-tazobactam is not considered a nephrotoxin, piperacillin-
tazobactam has been associated with impaired renal recovery and acute interstitial nephritis.24  
Meta-analyses have also suggested that vancomycin with piperacillin-tazobactam can increase 
the risk of nephrotoxicity.49,50  Hammond et al. conducted a meta-analysis and analyzed 14 
studies.49  They concluded an adjusted OR of 3.11 (95% CI, 1.77-5.47; p<0.001) for 
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nephrotoxicity was significant when vancomycin plus piperacillin-tazobactam was compared to 
vancomycin plus a beta-lactam antibiotic.  Similarly, Giuliano et al. evaluated 15 studies and 
calculated an overall OR of 3.65 (95% CI, 2.16-6.17; p<0.001) which was significant when 






CHAPTER 3: METHODOLOGY  
 
Study Design and Population 
 The study design is a single-institution retrospective cohort study at San Joaquin General 
Hospital (SJGH), a 196-bed county hospital located in Stockton, California.  The study was 
approved by the University of the Pacific (UOP) Institutional Review Board (IRB) with protocol 
number 20-122 and by the SJGH IRB with protocol number 20-303.  Medical records were 
reviewed at SJGH to identify hospitalized patients treated with IV vancomycin between June 
2019 to May 2020.  Patient identifiable information was removed upon completing the data 
collection.  Inclusion criteria were patients who were 18 years or older, required vancomycin for 
the treatment of an infection, on vancomycin for 48 hours or longer, and had one or more 
vancomycin concentrations collected.  Exclusion criteria were pregnancy, vancomycin continued 
for an infection diagnosed from a previous admission, any form of renal replacement therapy, 
vancomycin for surgical prophylaxis, and vancomycin continuous infusion. 
Data Collection  






 Comorbidities (e.g., preexisting liver disease, atherosclerotic cardiovascular disease 




Clinical characteristics.  The following clinical characteristics were collected. 
 SCr upon initiating vancomycin 
 Number of days on vancomycin 
 Suspected or diagnosed infection that indicated the use of vancomycin (e.g., SSTI, 
necrotizing fasciitis, osteomyelitis, pneumonia, bacteremia, endocarditis, septic joint, 
empyema) 
 
Isolated bacterial species.  Based on microbiological reports, patients were categorized 
as having MRSA, non-MRSA isolated bacterial species, or no isolated bacterial species.  
 MRSA: Isolated pathogen was MRSA. 
 Non-MRSA Isolated Bacterial Species: Isolated pathogen was not MRSA but was 
still covered by vancomycin’s spectrum of activity (e.g., Enterococcus spp. and 
MSSA). 
 
 No Isolated Bacterial Species: Isolated pathogen that is not covered by vancomycin’s 
spectrum of activity (e.g., gram-negative bacteria) or no positive cultures obtained 
during the hospital stay. 
 
 Special populations.  Medical charts were reviewed to place patients into vancomycin 
special populations of interest: ICU or critically ill patients and obese patients.  
 ICU or Critically Ill Patients: Patients who required an admission to the medical ICU 
or surgical ICU during their vancomycin course of treatment.  
 
 Obese Patients: Patients with a BMI greater than or equal to 30 kg/m2 upon initiating 
vancomycin. 
 
 Preexisting renal disease and concomitant nephrotoxins.  Medical charts were 
reviewed to assess for patients with preexisting renal disease and patients on concomitant 
nephrotoxins other than vancomycin. 
 Patients with Preexisting Renal Disease: Patients who have chronic kidney disease or 




 Patients on a Concomitant Nephrotoxin: Patients who received one or more doses of a 
loop diuretic, ACEI, ARB, NSAID, aminoglycoside, piperacillin-tazobactam, or IV 
contrast dye while on vancomycin.  
 
 Steady state AUC24h.  Using the Bayesian software program, PrecisePK (Version 
20.02.00, Healthware Inc., San Diego, CA), the patient’s age, gender, weight, height, SCr 
history, vancomycin dosing history, and vancomycin trough concentrations were entered into the 
program to calculate the AUC24h.  By assessing the concentration versus time graph, an interval 
when vancomycin’s steady state was reached and consistent was identified.  To decrease 
variability, the steady state was determined consistent if each of the dose’s peak concentrations 
was ±10% of its respective dosing regimen’s total average peak concentration.  The AUC24h for 
the steady state interval was then calculated using the equation below.  
 AUC 𝑖𝑛 ∗ =  
  
∗
   
∗
 (  )  (  )
∗ 24 hours  
 Endpoints.  The primary endpoint is vancomycin-associated nephrotoxicity using the 
definition of nephrotoxicity from the 2012 KDIGO Clinical Practice Guideline for AKI.  
 Vancomycin-Associated Nephrotoxicity: An increase in serum creatinine by 0.3 
mg/dL or more within 48 hours while on vancomycin or an increase in serum 
creatinine by 1.5 times the baseline which is known or presumed to have occurred 
within seven days of discontinuing vancomycin. 
 
The secondary endpoint is the estimated vancomycin AUC24h thresholds for 
nephrotoxicity for critically ill or ICU patients, obese patients, patients with preexisting renal 
disease, and patients on concomitant nephrotoxins.   
The tertiary endpoint is the predictive performances of the vancomycin AUC24h 
thresholds which include the following parameters:51,52  
 Positive Predictive Value (PPV): The probability of patients with a positive screening 
test truly having the condition.  For this study, the PPV is the probability of patients 
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with AUC24h values greater than the threshold for nephrotoxicity actually 
experiencing vancomycin-associated nephrotoxicity.  
 
 Negative Predictive Value (NPV): The probability of patients with a negative 
screening test truly not having the condition.  For this study, the NPV is the 
probability of patients with AUC24h values less than the threshold for nephrotoxicity 
actually not experiencing vancomycin-associated nephrotoxicity.  
 
 Sensitivity: The proportion of patients with a condition who are correctly identified 
by a screening test as truly having that condition (i.e., identifying true positives).  For 
this study, the sensitivity is the proportion of nephrotoxic patients who are correctly 
identified as experiencing vancomycin-associated nephrotoxicity based on the 
AUC24h threshold for nephrotoxicity.  
 
 Specificity: The proportion of patients without a condition who are correctly 
identified by a screening test as truly not having that condition (i.e., identifying true 
negatives).  For this study, the specificity is the proportion of non-nephrotoxic 
patients who are correctly identified as not experiencing vancomycin-associated 
nephrotoxicity based on the AUC24h threshold for nephrotoxicity.  
 
 Area Under the Receiver Operating Characteristic (ROC) Curve: A combined 
measure of sensitivity and specificity which numerically provides the overall 
predictive performance of a screening test or diagnostic test.  As the area under the 
ROC curve increases towards a maximum value of one, the overall performance of 
the test increases.  For this study, it is the overall predictive performance of the 
AUC24h threshold for nephrotoxicity.  
 
Data Analysis 
Baseline demographics and clinical characteristics were reported using descriptive 
statistics.  Additionally, the relationship between the patients’ baseline demographics and clinical 
characteristics and vancomycin-associated nephrotoxicity was analyzed by comparing 
nephrotoxic patients to non-nephrotoxic patients.  The independent t-test was used to detect 
statistical differences for continuous data while the Chi-square test and Fisher’s exact test were 
used to detect statistical differences for nominal data.  
Each special population that included at least ten nephrotoxic patients was further 
analyzed to derive the AUC24h threshold where the incidence of nephrotoxicity was most 
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disproportionate.  The AUC24h thresholds were estimated using CART analysis.  Their predictive 
performances were assessed by calculating their PPVs, NPVs, sensitivities, and specificities.  
The equations below were used to calculate the parameters and an example of the method is 
displayed in Table 2.  
 PPV =   x 100 
 NPV =   x 100 
 Sensitivity =   x 100 
 Specificity =   x 100 




Example of Calculating PPV, NPV, Sensitivity, and Specificity for AUC24h Thresholds Predicting 
Nephrotoxicity  
AUC24h Threshold of 616 mg*h/L Nephrotoxic Non-Nephrotoxic 
AUC24h above 
threshold 
Number of Patients 18 
True Positive (A) 
47 
False Positive (B) 
% Within Threshold 27.7% 
PPV 
72.3% 
% Within Nephrotoxicity 62.1% 
Sensitivity 
15.3% 
AUC24h less than 
threshold 
Number of Patients 11  False Negative (C) 
260 
True Negative (D) 
% Within Threshold 4.1% 95.9% 
NPV 
% Within Nephrotoxicity 37.9% 84.7% 
Specificity 
Abbreviations.  PPV, positive predictive value; NPV, negative predictive value; AUC24h, area 




Each CART-derived threshold’s predictive performance for predicting nephrotoxicity 
was then compared to the predictive performance of the AUC24h threshold of 600 mg*h/L that is 
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currently recommended by the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring 
guideline.  A generalized score statistic was used to detect statistical differences between the two 
thresholds’ PPVs and NPVs and the McNemar test was used to detect statistical differences 
between their sensitivities and specificities.  When comparing the predictive performances 
between the CART-derived thresholds and the guideline threshold, maximizing the PPV and 
sensitivity is desired over maximizing the NPV or specificity.  A higher PPV increases the 
likelihood of identifying AUC24h values that result in nephrotoxicity.  Moreover, a higher 
sensitivity increases the accuracy of the threshold in predicting patients who truly have 
nephrotoxicity and decreases the probability of having a false negative.  In addition to comparing 
their predictive values, sensitivities, and specificities, ROC curves were analyzed to compare the 
thresholds’ overall predictive performances. 
Prior to identifying and assessing the AUC24h threshold for each special population, a 
validity test was performed to assess the method proposed by this study.  This was achieved by 
applying the method to the general population.  The method was considered validated if the 
CART-derived threshold for the general population was determined to be insignificant when 
compared to the guideline threshold that was based on preexisting literature. 
Lastly, to evaluate for any confounding factors, patients were divided into two groups: 
patients who had an AUC24h less than or equal to the CART-derived threshold and those who had 
an AUC24h above the CART-derived threshold.  Bivariate comparisons between the two groups’ 
baseline demographics, clinical characteristics, and types of infection were then conducted.  The 
independent t-test was used to detect statistical differences for continuous data and the Chi-
square test and Fisher’s exact test were used to detect statistical differences for nominal data.  
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In this study, p-values of less than or equal to 0.05 were considered statistically 
significant.  Statistical analyses such as the independent t-test, Chi-Square test, Fisher’s exact 
test, and CART analysis were performed using IBM SPSS software (Version 27.0, IBM 
Corporation, Armonk, NY).  The generalized score statistic and McNemar test were performed 




CHAPTER 4: RESULTS 
 
Description of Cohort 
A total of 336 patients was included in the study.  Baseline demographics of the study 
population are presented in Table 3.  A majority of the patients were male (84.8%) and 
Caucasian (41.4%).  Among the study population, mean age was 57.1 years (standard deviation 
[SD], 14.9 years), mean weight was 86.9 kilograms (SD, 28.1 kilograms), and mean height was 
173.0 centimeters (SD, 11.4 centimeters).  Common comorbidities included ASCVD (21.7%), 




Characteristic Value for Patients (n=336) 






Age (years), mean ± SD 57.1 ± 14.8 
Weight (kg), mean ± SD 86.9 ± 28.1 
Height (cm), mean ± SD 173.0 ± 11.4 
Ethnicity/Race, no. (%) 
Caucasian 
Hispanic 











Comorbidity, no. (%) 
Preexisting Liver Disease 
















Clinical characteristics of the study population are illustrated in Table 4.  The mean SCr  
upon initiating vancomycin was 1.06 mg/dL (SD, 0.69 mg/dL) and the mean duration of therapy 
was 7.2 days (SD, 4.6 days).  The most common vancomycin indications were SSTI (34.2%), 
pneumonia (32.7%), and bacteremia (24.1%), and approximately a quarter of the population’s 




Clinical Characteristics  
Characteristic Value for Patients (n=336) 
Vancomycin Indication, no. (%) 
SSTI 


















Isolated Organism, no. (%) 
MRSA 
Non-MRSA 





Initial Serum Creatinine (mg/dL), mean ± SD 1.06 ± 0.69 
Vancomycin Duration (days), mean ± SD 7.2 ± 4.6 




Comparison of Patient Characteristics Between Non-Nephrotoxic and Nephrotoxic Patients 
The bivariate comparison of the baseline demographics and clinical characteristics 
between patients who had nephrotoxicity and those who did not is displayed in Table 5.  
Twenty-nine (8.6%) patients experienced nephrotoxicity.  Patients who experienced 
nephrotoxicity were more likely to have preexisting renal disease (34.5% vs. 14.4%; p=0.014) 
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and had significantly higher SCr levels upon initiating vancomycin (1.52 ± 0.95 mg/dL vs. 1.02 
±. 0.65 mg/dL; p<0.001).  Furthermore, the nephrotoxic group had significantly more critically 
ill or ICU patients (75.9% vs. 30.6%; p<0.001) and patients who received concomitant loop 

















Age (years), mean ± SD 
Male, no. (%) 
 
56.7 ± 14.7 
260 (84.7) 
 






Preexisting Liver Disease, no. (%) 
ASCVD, no. (%) 
Heart Failure, no. (%) 
Diabetes, no. (%) 



















Selected Special Populations 
Critically Ill or ICU, no. (%) 
Obese (BMI≥30 kg/m2), no. (%) 
Preexisting Renal Disease, no. (%) 
Concomitant Nephrotoxin 
Loop Diuretic, no. (%) 
ACEI/ARB, no. (%) 
NSAID, no. (%) 
Aminoglycoside, no. (%) 
Piperacillin/tazobactam, no. (%) 


































Vancomycin Treatment Data 
Initial SCr (mg/dL), mean ± SD 
Vancomycin Indication 
SSTI, no. (%) 
Osteomyelitis, no. (%) 
Pneumonia, no. (%) 
Bacteremia, no. (%) 
Vancomycin Duration (days), mean ± SD 
 






7.1 ± 4.6 
 















* P-value was <0.05. 
a P-value was calculated using independent t-test. 
b P-value was calculated using Fisher’s exact test due to one or more expected values being <5.  
All other p-values were calculated using chi-square test.   
Abbreviations.  ASCVD, atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, 
angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, 
nonsteroidal anti-inflammatory drug; SSTI, skin and soft tissue infection; SCr, serum creatinine. 
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Method Validation by Analyzing the General Population 
 For the general population of 336 patients, the CART analysis showed that the incidence 
of nephrotoxicity was significantly higher for patients with AUC24h values greater than 616 








  Table 6, Table 7, and Figure 2 compare the predictive performances of the CART-
derived threshold and guideline threshold.  No statistical differences were detected between their 
PPVs (p=0.163), NPVs (p=0.286), and sensitivities (p=0.157).  Moreover, their overall 
predictive performances were noninferior to one another as they had similar areas under the ROC 
curves (0.734 vs. 0.747; p=0.589).  The threshold of 616 mg*h/L was consistent with previous 
studies and was associated with practically similar predictive performances to the guideline 







Predictive Performances of CART-Derived AUC24h Threshold and Guideline Threshold for the 
General Population 
Predictive Performance AUC24h 616 mg*h/L AUC24h 600 mg*h/L P-value 
PPV (%) 27.7 25.0 0.163a,c 
NPV (%) 95.9 96.5 0.286a,d 
Sensitivity (%) 62.1 69.0 0.157b,e 
Specificity (%) 84.7 80.5 <0.001b,f* 
Area under ROC Curve (95% CI) 0.734 (0.626–0.841) 0.747 (0.646–0.849) 0.589g 
* P-value was <0.05 
a P-value was calculated using generalized score statistic. 
b P-value was calculated using McNemar test.  
c PPV data derived from 145 observations (65 patients with AUC24h >616 mg*h/L and 80 
patients with AUC24h >600 mg*h/L). 
d NPV data derived from 527 observations (271 patients with AUC24h <616 mg*h/L and 256 
patients with AUC24h <600 mg*h/L). 
e Sensitivity data derived from 29 nephrotoxic patients. 
f Specificity data derived from 307 non-nephrotoxic patients. 
g ROC analysis derived from 336 patients.  
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; PPV, positive 





Figure 2.  Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold 








AUC24h of General Population That Experienced Nephrotoxicity  
 AUC24h ≤600 mg*h/L  AUC24h >600 mg*h/L  
AUC24h ≤616 mg*h/L  9 (31.0) 2 (6.9) 
AUC24h >616 mg*h/L  0 (0) 18 (62.1) 
P-value=0.157 (based on McNemar test); n=29 




Special Populations and Nephrotoxic Patients 
Table 8 summarizes the total number of patients and patients with nephrotoxicity in each 
special population.  Special populations of interest included critically ill or ICU patients (34.5%), 
obese patients (33.0%), patients with preexisting renal disease (16.1%), and patients on 
concomitant nephrotoxins (76.8%).  The most common concomitant nephrotoxins were loop 
diuretics (37.5%), ACEIs or ARBs (22.0%), and IV contrast dyes (42.3%). 
There were at least ten nephrotoxic patients in critically ill or ICU patients, obese 
patients, patients with preexisting renal disease, and patients on concomitant loop diuretics.  The 
CART-derived AUC24h thresholds were derived for these special populations and their predictive 
performances were assessed, as described in the method section.  Contrastingly, less than ten 
nephrotoxic patients were observed in patients on concomitant ACEIs or ARBs, NSAIDs, 
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes.  Due to inadequate sample sizes 







Special Populations and Nephrotoxic Patients  
Special Population Total Patients, no. Nephrotoxic Patients, no. 
Critically Ill or ICU Patient 
Obese Patient (BMI≥30 kg/m2) 
Patient with Preexisting Renal Disease 



























Abbreviations.  ICU, intensive care unit; BMI, body mass index; NSAID, nonsteroidal anti-
inflammatory drug; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II 




CART-Derived Vancomycin AUC24h Thresholds for Nephrotoxicity 
Critically Ill or ICU Patients 
Of the 336 patients, 116 (34.5%) patients were identified to be critically ill or ICU 
patients.  The CART analysis showed that incidence of nephrotoxicity was significantly higher 
for critically ill or ICU patients with AUC24h values greater than 544 mg*h/L (35.8% vs. 4.8%; 









Table 9 and Figure 4 display the predictive performances of the CART-derived AUC24h 
threshold and guideline threshold for critically ill or ICU patients.  The CART-derived threshold 
had a significantly higher NPV (p=0.037) and sensitivity (p=0.031).  In other words, out of 22 
ICU patients with nephrotoxicity, the threshold of 544 mg*h/L identified six (27.3%) more 
nephrotoxic patients than the threshold of 600 mg*h/L (Table 10).  Moreover, the overall 
predictive performance of the CART-derived threshold was shown to be 0.058 (8.4%) higher 
than that of the guideline threshold based on the ROC curve analysis (0.751 vs. 0.693; p=0.278).  






Predictive Performances of CART-Derived AUC24h Threshold and Guideline Threshold for 
Critically Ill and ICU Patients  
Predictive Performance AUC24h 544 mg*h/L AUC24h 600 mg*h/L  P-value 
PPV (%) 35.8 40.6 0.337a,c 
NPV (%) 95.2 89.3 0.037a,d* 
Sensitivity (%) 86.4 59.1 0.014b,e* 
Specificity (%) 63.8 79.8 <0.001b,f* 
Area under ROC Curve (95% CI) 0.751 (0.646–0.856) 0.694 (0.563–0.825) 0.278g 
* P-value was <0.05 
a P-value was calculated using generalized score statistic. 
b P-value was calculated using McNemar test.  
c PPV data derived from 85 observations (53 patients with AUC24h >544 mg*h/L and 32 patients 
with AUC24h >600 mg*h/L). 
d NPV data derived from 147 observations (63 patients with AUC24h <544 mg*h/L and 84 
patients with AUC24h <600 mg*h/L). 
e Sensitivity data derived from 22 nephrotoxic patients. 
f Specificity data derived from 94 non-nephrotoxic patients. 
g ROC analysis derived from 116 patients.  
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; ICU, intensive 






Figure 4.  Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold 








AUC24h of Critically Ill or ICU Patients Who Experienced Nephrotoxicity  
 AUC24h ≤600 mg*h/L  AUC24h >600 mg*h/L  
AUC24h ≤544 mg*h/L  3 (13.6) 0 (0) 
AUC24h >544 mg*h/L  6 (27.3) 13 (59.1) 
P-value=0.014 (based on McNemar test); n=22 





Table 11 provides the bivariate comparison between critically ill or ICU patients with 
AUC24h values less than or equal to 544 mg*h/L and those with AUC24h values greater than 544 
mg*h/L.  No confounding factors were found that can impact the risk of vancomycin-associated 







Patient Characteristics Between Critically Ill or ICU Patients with AUC24h Above and Below 










Age (years), mean ± SD 
Male, no. (%) 
 
53.7 ± 16.0 
53 (84.1) 
 






Preexisting Liver Disease, no. (%) 
ASCVD, no. (%) 
Heart Failure, no. (%) 
Diabetes, no. (%) 



















Selected Special Populations 
Obese (BMI≥30 kg/m2), no. (%) 
Preexisting Renal Disease, no. (%) 
Concomitant Nephrotoxin, no. (%) 
Loop Diuretic, no. (%) 
ACEI/ARB, no. (%) 
NSAID, no. (%) 
Aminoglycoside, no. (%) 
Piperacillin/tazobactam, no. (%) 































Vancomycin Treatment Data 
Initial SCr (mg/dL), mean ± SD 
Vancomycin Indication 
SSTI, no. (%) 
Osteomyelitis, no. (%) 
Pneumonia, no. (%) 
Bacteremia, no. (%) 
Vancomycin Duration (days), mean ± SD 
Nephrotoxicity, no. (%) 
 






8.2 ± 4.3 
3 (4.8) 
 

















* P-value was <0.05 
a P-value was calculated using independent t-test. 
b P-value was calculated using Fisher’s exact test due to one or more expected values being <5.  
All other p-values were calculated using chi-square test.   
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; ASCVD, 
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory 






Of the 336 patients, 111 (33.0%) patients were identified to be obese and had a mean 
BMI of 38.2 kg/m2 (SD, 9.2 kg/m2).  The CART analysis showed that incidence of 
nephrotoxicity was significantly higher for obese patients with AUC24h values greater than 586 




Figure 5.  CART-derived AUC24h nephrotoxicity threshold for obese patients. 
 
 
Table 12, Table 13, and Figure 6 show no statistical difference between the predictive 
performances of the CART-derived threshold and guideline threshold.  No statistical differences 
were found between their PPVs (p=0.968), NPVs (p=0.357), sensitivities (p=0.317), and 
specificities (p=0.083).  Additionally, the two thresholds had a difference in areas under the 
ROC curves of 0.035 (4.7%) and their overall predictive performances were noninferior to one 






Predictive Performances of CART-Derived AUC24h Threshold and Guideline Threshold for 
Obese Patients  
Predictive Performance AUC24h 586 mg*h/L AUC24h 600 mg*h/L  P-value 
PPV (%) 25.8 25.9 0.968a,c 
NPV (%) 97.5 96.4 0.357a,d 
Sensitivity (%) 80.0 70.0 0.317b,e 
Specificity (%) 77.2 80.2 0.083b,f 
Area under ROC Curve (95% CI) 0.786 (0.635–0.938) 0.751 (0.579–0.923) 0.278g 
a P-value was calculated using generalized score statistic. 
b P-value was calculated using McNemar test.  
c PPV data derived from 58 observations (31 patients with AUC24h >586 mg*h/L and 27 patients 
with AUC24h >600 mg*h/L). 
d NPV data derived from 164 observations (80 patients with AUC24h <586 mg*h/L and 84 
patients with AUC24h <600 mg*h/L). 
e Sensitivity data derived from 10 nephrotoxic patients. 
f Specificity data derived from 101 non-nephrotoxic patients. 
g ROC analysis derived from 111 patients.  
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; PPV, positive 





Figure 6.  Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold 








AUC24h of Obese Patients Who Experienced Nephrotoxicity  
 AUC24h ≤600 mg*h/L  AUC24h >600 mg*h/L  
AUC24h ≤586 mg*h/L  2 (20.0) 0 (0) 
AUC24h >586 mg*h/L  1 (10.0) 7 (70.0) 
P-value=0.317 (based on McNemar test); n=10 
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours. 
 
 
The bivariate comparison of obese patients with AUC24h values less than or equal to 586 
mg*h/L versus those with AUC24h values greater than 586 mg*h/L is displayed in Table 14.  No 
confounding factors that can impact the risk of vancomycin-associated nephrotoxicity between 
















Age (years), mean ± SD 
Male, no. (%) 
BMI (kg/m2), mean ± SD 
 
54.1 ± 15.0 
67 (83.8) 
37.7 ± 8.6 
 
57.8 ± 9.0 
26 (83.9) 






Preexisting Liver Disease, no. (%) 
ASCVD, no. (%) 
Heart Failure, no. (%) 
Diabetes, no. (%) 
Hypertension, no. (%) 
 
12 (15.0) 
















Selected Special Populations 
Critically Ill or ICU, no. (%) 
Preexisting Renal Disease, no. (%) 
Concomitant Nephrotoxin, no. (%) 
Loop Diuretic, no. (%) 
ACEI/ARB, no. (%) 
NSAID, no. (%) 
Aminoglycoside, no. (%) 
Piperacillin/tazobactam, no. (%) 































Vancomycin Treatment Data 
Initial SCr (mg/dL), mean ± SD 
Vancomycin Indication 
SSTI, no. (%) 
Osteomyelitis, no. (%) 
Pneumonia, no. (%) 
Bacteremia, no. (%) 
Vancomycin Duration (days), mean ± SD 
Nephrotoxicity, no. (%) 
 






6.8 ± 3.4 
2 (2.5) 
 

















* P-value was <0.05 
a P-value was calculated using independent t-test. 
b P-value was calculated using Fisher’s exact test due to one or more expected values being <5.  
All other p-values were calculated using chi-square test.   
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; BMI, body mass 
index; ASCVD, atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, 
angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, 




Patients with Preexisting Renal Disease 
Of the 336 patients, 54 (16.1%) patients were considered to have preexisting chronic 
kidney disease or AKI upon admission.  The CART analysis showed that incidence of 
nephrotoxicity was significantly higher for patients with AUC24h values greater than  539 









Table 15 and Figure 8 compare the predictive performance of the CART-derived 
AUC24h threshold and guideline threshold for patients with preexisting renal disease.  The 
CART-derived threshold had a significantly higher NPV (p=0.025) and sensitivity (p=0.025).  In 
other words, out of ten nephrotoxic patients with preexisting renal disease, the threshold of 539 
mg*h/L identified five (50.0%) more nephrotoxic patients than the guideline threshold of 600 
mg*h/L (Table 16).  Although statistical significance was not achieved due to a small sample 
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size, the overall predictive performance of the 539 mg*h/L threshold was shown to be 0.148 
(24.6%) higher than that of the 600 mg*h/L threshold (0.750 vs. 0.602; p=0.096).  
 
Table 15  
Predictive Performances of CART-Derived AUC24h Threshold and Guideline Threshold for 
Patients with Preexisting Renal Disease  
Predictive Performance AUC24h 539 mg*h/L AUC24h 600 mg*h/L  P-value 
PPV (%) 31.3 27.8 0.653a,c 
NPV (%) 100 86.1 0.025a,d* 
Sensitivity (%) 100 50.0 0.025b,e* 
Specificity (%) 50.0 70.5 0.003b,f* 
Area under ROC Curve (95% CI) 0.750 (0.617–0.883) 0.602 (0.401–0.803) 0.096g 
* P-value was <0.05 
a P-value was calculated using generalized score statistic. 
b P-value was calculated using McNemar test.  
c PPV data derived from 50 observations (32 patients with AUC24h >539 mg*h/L and 18 patients 
with AUC24h >600 mg*h/L). 
d NPV data derived from 58 observations (22 patients with AUC24h <539 mg*h/L and 36 patients 
with AUC24h <600 mg*h/L). 
e Sensitivity data derived from 10 nephrotoxic patients. 
f Specificity data derived from 44 non-nephrotoxic patients. 
g ROC analysis derived from 54 patients.  
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; PPV, positive 





Figure 8.  Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold 






AUC24h of Patients with Preexisting Renal Disease Who Experienced Nephrotoxicity  
 AUC24h ≤600 mg*h/L  AUC24h >600 mg*h/L  
AUC24h ≤539 mg*h/L  0 (0) 0 (0) 
AUC24h >539 mg*h/L  5 (50.0) 5 (50.0) 
P-value=0.025 (based on McNemar test); n=10 





Table 17 shows no confounding factors that can impact the risk of vancomycin-
associated nephrotoxicity between the patients with AUC24h values less than or equal to the 







Patient Characteristics Between Patients with Preexisting Renal Disease with AUC24h Above and 










Age (years), mean ± SD 
Male, no. (%) 
 
60.7 ± 12.3 
21 (95.5) 
 






Preexisting Liver Disease, no. (%) 
ASCVD, no. (%) 
Heart Failure, no. (%) 
Diabetes, no. (%) 



















Selected Special Populations 
Critically Ill or ICU  
Obese (BMI≥30 kg/m2), no. (%) 
Concomitant Nephrotoxin 
Loop Diuretic, no. (%) 
ACEI/ARB, no. (%) 
NSAID, no. (%) 
Aminoglycoside, no. (%) 
Piperacillin/tazobactam, no. (%) 































Vancomycin Treatment Data 
Initial SCr (mg/dL), mean ± SD 
Vancomycin Indication 
SSTI, no. (%) 
Osteomyelitis, no. (%) 
Pneumonia, no. (%) 
Bacteremia, no. (%) 
Vancomycin Duration (days), mean ± SD 
Nephrotoxicity, no. (%) 
 






7.0 ± 3.1 
0 (0) 
 

















* P-value was <0.05 
a P-value was calculated using independent t-test. 
b P-value was calculated using Fisher’s exact test due to one or more expected values being <5.  
All other p-values were calculated using chi-square test.   
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; ASCVD, 
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory 




Patients on Concomitant Loop Diuretics 
The CART-derived AUC24h threshold for nephrotoxicity for the 126 (37.5%) patients on 
a concomitant loop diuretic was 543 mg*h/L.  Incidence of nephrotoxicity was significantly 
higher for patients with AUC24h values greater than 543 mg*h/L (34.5% vs. 2.9%; p<0.001) 
(Figure 9).  
 
 





Table 18 and Figure 10 provide the predictive performances of the CART-derived 
threshold and guideline threshold for patients on a concomitant loop diuretic.  The CART-
derived threshold had a significantly higher NPV (p=0.028) and sensitivity (p=0.014).  In other 
words, out of 22 nephrotoxic patients on a concomitant loop diuretic, the threshold of 543 
mg*h/L identified six (27.3%) more nephrotoxic patients than the guideline threshold (Table 
19).  Although statistical significance was not met due to the small sample size, the ROC curve 
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analysis showed that the CART-derived threshold’s overall predictive performance was 0.055 




Predictive Performances of CART-Derived AUC24h Threshold and Guideline Threshold for 
Patients on Concomitant Loop Diuretics 
Predictive Performance AUC24h 543 mg*h/L AUC24h 600 mg*h/L  P-value 
PPV (%) 34.5 40.0 0.235a,c 
NPV (%) 97.1 91.2 0.028a,d* 
Sensitivity (%) 90.9 63.6 0.014b,e* 
Specificity (%) 63.5 79.8 <0.001b,f* 
Area under ROC Curve (95% CI) 0.772 (0.677-0.867) 0.717 (0.591-0.844) 0.292g 
* P-value was <0.05 
a P-value was calculated using generalized score statistic. 
b P-value was calculated using McNemar test.  
c PPV data derived from 93 observations (58 patients with AUC24h >543 mg*h/L and 35 patients 
with AUC24h >600 mg*h/L). 
d NPV data derived from 159 observations (68 patients with AUC24h <543 mg*h/L and 91 
patients with AUC24h <600 mg*h/L). 
e Sensitivity data derived from 22 nephrotoxic patients. 
f Specificity data derived from 104 non-nephrotoxic patients. 
g ROC analysis derived from 126 patients.  
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; PPV, positive 





Figure 10.  Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold 






AUC24h of Patients on Concomitant Loop Diuretics Who Experienced Nephrotoxicity  
 AUC24h ≤600 mg*h/L  AUC24h >600 mg*h/L  
AUC24h ≤543 mg*h/L  2 (9.1) 0 (0) 
AUC24h >543 mg*h/L  6 (27.3) 14 (63.6) 
P-value=0.014 (based on McNemar test); n=22 
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours. 
 
 
No confounding factors were found when comparing patients on concomitant loop 
diuretics with AUC24h values less than or equal to 543 mg*h/L to those with AUC24h values 










Patient Characteristics Between Patients on Concomitant Loop Diuretics with AUC24h Above 










Age (years), mean ± SD 
Male, no. (%) 
 
58.9 ± 13.8 
63 (92.6) 
 






Preexisting Renal Disease, no. (%) 
Preexisting Liver Disease, no. (%) 
ASCVD, no. (%) 
Heart Failure, no. (%) 
Diabetes, no. (%) 






















Selected Special Populations 
Critically Ill or ICU, no. (%) 
Obese (BMI≥30), no. (%) 













Vancomycin Treatment Data 
Initial SCr (mg/dL), mean ± SD 
Vancomycin Indication 
SSTI, no. (%) 
Osteomyelitis, no. (%) 
Pneumonia, no. (%) 
Bacteremia, no. (%) 
Vancomycin Duration (days), mean ± SD 
Nephrotoxicity, no. (%) 
 






8.2 ± 4.0 
2 (2.9) 
 

















* P-value <0.05 
a P-value was calculated using independent t-test. 
b P-value was calculated using Fisher’s exact test due to one or more expected values being <5.  
All other p-values were calculated using chi-square test.   
Abbreviations.  AUC24h, area under the concentration-time curve over 24 hours; ASCVD, 
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory 







CHAPTER 5: DISCUSSION 
 
 
This retrospective cohort study identified and examined the vancomycin AUC24h 
thresholds for nephrotoxicity for critically ill patients, obese patients, patients with preexisting 
renal disease, and patients on concomitant nephrotoxins.  It is the first study to perform analyses 
on vancomycin special populations to assess for AUC24h thresholds for nephrotoxicity that differ 
from the guideline threshold of 600 mg*h/L.  Compared to previous studies of a similar nature, 
this study adopted a less stringent definition of vancomycin-associated nephrotoxicity to capture 
more nephrotoxic patients.8,12,32-36  Previous studies defined vancomycin-associated 
nephrotoxicity as an increase in SCr by 0.5 mg/dL or more or a 50% increase from baseline on 
two or more consecutive measures.  On the other hand, this study adapted the definition of AKI 
from the 2012 KDIGO Clinical Practice Guideline for AKI and defined vancomycin-associated 
nephrotoxicity as an increase in SCr by 0.3 mg/dL or more within 48 hours or a 50% increase 
from baseline which is known or presumed to have occurred within seven days of discontinuing 
vancomycin.37  Among the 336 patients included, 29 (8.6%) patients met the definition of 
nephrotoxicity.  Consistent with prior studies’ findings, an increased risk of nephrotoxicity was 
associated with critical illness, preexisting renal disease, higher initial serum creatinine levels, 
and concomitant loop diuretics. 
 Previous studies used various AUC parameters (e.g., AUC0-24h, AUC24-48h, and AUC24h) 
and methods to assess their CART-derived AUC thresholds.8,12,32-36  Prior to analyzing the 
special populations, the general population was analyzed to validate the method proposed in this 
study.  For the general population, a CART-derived AUC24h threshold of greater than 616 
mg*h/L was significantly associated with an increased risk of nephrotoxicity.  The difference in 
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predictive performances between the CART-derived threshold and guideline threshold was not 
statistically significant.  No statistical differences were detected between the two thresholds’ 
PPVs, NPVs, sensitivities, and areas under the ROC curves.  Because the threshold of 616 
mg*h/L was consistent with preexisting literature, the proposed method to estimate the CART-
derived AUC24h thresholds for nephrotoxicity and to assess their predictive performances was 
validated.  
Although PPV, NPV, sensitivity, and specificity were estimated, PPV and sensitivity 
were given greater weight when determining the threshold for nephrotoxicity with the optimal 
predictive performance.  For predicting nephrotoxicity, a higher PPV increases the likelihood of 
identifying patients with vancomycin exposures that result in nephrotoxicity.  In addition, a 
higher sensitivity increases the accuracy of the AUC24h threshold in detecting a true positive for 
nephrotoxicity and decreases the probability of having a false negative.   
Critically ill patients frequently need larger doses of vancomycin due to their high acuity 
and their typically more resistant pathogens.13,41  Additionally, they are more inclined to have 
hemodynamic instability, renal hypoperfusion, and an increased Vd of vancomycin that can 
increase their risk of nephrotoxicity.  ICU residence and high APACHE II scores are 
independently associated with an increased risk of nephrotoxicity (aOR, 3.25; 95% CI, 1.18-
9.98; p=0.02 and 22.9 ± 7.4 vs. 18.2 ± 8.5; p=0.006, respectively).16,33  In this study, a CART-
derived threshold of 544 mg*h/L was identified for critically ill patients.  Compared to the 
guideline threshold, the CART-derived threshold had a similar PPV and a significantly higher 
sensitivity.  Therefore, this study demonstrates that a lower vancomycin AUC24h threshold than 
the guideline threshold of 600 mg*h/L should be considered in critically ill patients to decrease 
the risk of nephrotoxicity.  
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Currently, there are conflicting studies on the relationship between obesity and the risk of 
nephrotoxicity.  Davies et al. did not associate obesity with an increased risk of nephrotoxicity 
(RR, 0.98; 95% CI, 0.93-1.04; p=0.59).45  The current study also did not associate obesity with 
an increased risk of nephrotoxicity (32.9% vs. 34.5%, p=0.862).  However, other studies have 
shown weight to be associated with an increased risk of nephrotoxicity (OR, 1.02; 95% CI, 1.00-
1.03) and weight greater than 100 kg was an independent predictor of nephrotoxicity (OR, 2.74; 
95% CI, 1.27-5.91).14,15  Researchers hypothesize that the increased risk of nephrotoxicity is due 
to obese patients having an increased Vd of vancomycin that leads to disproportionately larger 
doses and a more intensive vancomycin exposure profile.42,43  However, the AUC24h parameter 
already accounts for vancomycin dosing and is directly proportional to the amount of 
vancomycin administered.  Thus, even if obesity is associated with an increased risk of 
nephrotoxicity, the AUC24h threshold for nephrotoxicity is suspected to not be lowered in obese 
patients.  In this study, a significant CART-derived threshold was not identified for obese 
patients.  Compared to the guideline threshold, the CART-derived threshold of 586 mg*h/L did 
not have a statistically significant PPV, NPV, sensitivity, specificity, or area under the ROC 
curve.  Therefore, this study supports the continued use of 600 mg*h/L as the AUC24h threshold 
for nephrotoxicity in obese patients. 
Studies have shown that patients with preexisting renal disease are associated with a 
higher risk of nephrotoxicity as vancomycin is predominantly eliminated renally.17,20  A 
significant CART-derived threshold of 539 mg*h/L was identified in patients with preexisting 
renal disease.  Compared to the guideline threshold, the AUC24h threshold of 539 mg*h/L had a 
comparable PPV and a significantly higher sensitivity.  To minimize the risk of vancomycin-
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associated nephrotoxicity, this study supports using a lower vancomycin AUC24h threshold than 
the guideline threshold of 600 mg*h/L in patients with preexisting renal disease.  
A prospective study determined that patients on concomitant nephrotoxins were 
significantly associated with an increased risk of nephrotoxicity (91% vs. 20%; p<0.001).19  
Concomitant nephrotoxins remained a significant predictor of nephrotoxicity after performing a 
multivariate analysis (p=0.003).  Concomitant loop diuretics increase the risk of vancomycin-
associated nephrotoxicity by 43-fold.18  The current study identified a significant CART-derived 
threshold of 543 mg*h/L for patients on concomitant loop diuretics.  The CART-derived 
threshold had a comparable PPV but a significantly higher sensitivity compared to the guideline 
threshold.  For patients on concomitant loop diuretics, a lower vancomycin AUC24h threshold 
than the guideline threshold of 600 mg*h/L should be considered to minimize the risk of 
nephrotoxicity. 
Other concomitant nephrotoxins such as renin-angiotensin system blockers, NSAIDs, 
aminoglycosides, piperacillin-tazobactam, and IV contrast dyes have also demonstrated 
synergistic activity with vancomycin in the development of nephrotoxicity.18,20,48-50  However, 
less than ten nephrotoxic patients were observed and therefore CART analysis was not 
performed in these special populations.  With the exception of patients on IV contrast dyes, these 
special populations had less than ten nephrotoxic patients due to their small sample sizes.  
Despite having an adequate sample size of patients who received IV contrast dyes, less than 10 
nephrotoxic patients were observed.  This was hypothesized to be due to patients commonly 
receiving sodium bicarbonate or acetylcysteine prior to receiving IV contrast dyes at SJGH to 
minimize the risk of nephrotoxicity.  Further research is needed to determine if the upper AUC24h 
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threshold is consistent or varies when used in patients on concomitant ACEIs, ARBs, NSAIDs, 
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes.  
The CART-derived thresholds identified for critically ill patients, patients with 
preexisting renal disease, and patients on concomitant loop diuretics are inherently able to 
provide AUC24h thresholds where the risk of nephrotoxicity is most disproportionate.  However, 
studies theorize that the incidence of vancomycin-associated nephrotoxicity increases along the 
AUC24h continuum.4  Therefore, it is important to recognize that the study’s findings of AUC24h 
thresholds that are lower than the guideline threshold serve as a guidance for clinicians to be 
cognizant of the potential synergistic nephrotoxicity risk when dosing vancomycin in special 
populations such as critically ill patients, patients with preexisting renal disease, and patients on 
concomitant loop diuretics.  Clinicians should consider dosing vancomycin more conservatively 
in these special populations.  
Study Limitations 
The current study has several limitations that are mostly inherent to the study’s single-
center, retrospective study design.  Foremost, a majority of the patients were male and 
Caucasian.  However, no study has reported significantly different AUC24h thresholds for 
nephrotoxicity based on gender or race.  Based on statistical analysis using this study’s 
population, the incidence of nephrotoxicity was not significantly different between males and 
females (p=0.828) and between Caucasians and non-Caucasians (p=0.145).  Therefore, the 
dominant male and Caucasian population may not limit the application of the current study to 
females or other races.   
Moreover, not all of the patients included in the nephrotoxicity analysis had 
Staphylococcus aureus infections.  Patients on vancomycin due to suspected MRSA but then 
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finalized with other gram-positive or gram-negative pathogens were still included in the 
nephrotoxicity analysis.  However, the inclusion of non-MRSA infections was considered 
appropriate as the main endpoint measurement was nephrotoxicity rather than efficacy of the 
drug exposure.  In addition, it mimics real-life clinical practice settings where causative 
pathogens are commonly yet to be identified during the initial course of vancomycin.  
Additionally, trough concentrations were primarily used to estimate the Bayesian-derived 
AUC24h rather than both peak and trough concentrations.  However, Ho et al. demonstrated 
significant correlations between the Bayesian-derived AUC24h values estimated from one sample 
and those from two samples (p <0.001).53  Therefore, the CART-derived AUC24h thresholds 
derived from predominately trough concentrations would not be meaningfully different from 
those derived from peak and trough concentrations.   
Lastly, this study did not include the AUC24h/MICBMD threshold for efficacy of 
vancomycin.  This outcome had been planned in the early state of the research and the study 
initially aimed to identify the CART-derived AUC24h/MICBMD thresholds associated with 
treatment success in MRSA-associated infections and special populations such as critically ill 
patients, amphetamine users, IVDU, and patients on concomitant immunosuppressants.  
However, only 13 (3.9%) patients had clinical failure. Furthermore, only 81 (24.3%) patients 
were isolated with MRSA and 17 (21.0%) of those patients had AUC24h/MICBMD ratios less than 
400.  Therefore, this study focused only on the AUC24h threshold for nephrotoxicity.   
Future Directions 
As more hospitals continue to transition from trough-based monitoring to AUC24h-based 
monitoring, further studies should be conducted to establish a relationship between the 
vancomycin AUC24h threshold for nephrotoxicity and special populations such as critically ill 
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patients, obese patients, patients with preexisting renal disease, and patients on concomitant 
nephrotoxins.  Additional studies should also be conducted to assess the impact on the AUC24h 
threshold when patients meet the description of more than one special population.  
A follow-up multicenter, prospective study is warranted to validate the lower CART-
derived AUC24h that was identified in critically ill patients, patients with preexisting renal 
disease, and patients on concomitant loop diuretics.  The impact on the AUC24h threshold when 
patients meet the description of more than one special population should also be considered.  
Furthermore, conducting the study at multiple institutions can increase the sample size of the 
study.  Having more nephrotoxic patients in each special population can improve the estimation 
of the CART-derived thresholds for nephrotoxicity and the assessment of their predictive 
performances.  Additionally, it will allow further analyses on special populations that the current 
study was unable to analyze (e.g., patients on concomitant ACEIs, ARBs, NSAIDs, 
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes).  Moreover, collecting both peak 
and trough concentrations would be ideal to maximize the accuracy of estimating the AUC24h.  
Additional parameters can also be collected to better describe the special populations. For 
example, a scoring system such as the APACHE II can be used to stratify critically ill patients 
based on the severity of their critical illness.  Similarly, recording the dose and duration of the 
concomitant nephrotoxins can help determine if conservative vancomycin dosing needs to be 
considered in patients who receive a single dose or low doses of a concomitant nephrotoxin.  
A multicenter, prospective study is also needed to investigate the generalizability of the 
proposed vancomycin AUC24h/MICBMD threshold of 400 for clinical efficacy in different MRSA-
associated infections and vancomycin special populations.  This will ensure that the study is 
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adequately powered and includes enough incidences of MRSA infections and clinical failures to 




CHAPTER 6: CONCLUSION 
 
 
For critically ill patients, patients with preexisting renal disease, and patients on 
concomitant loop diuretics, a lower vancomycin AUC24h threshold for nephrotoxicity such as 
544 mg*h/L, 539 mg*h/L, and 543 mg*h/L, respectively, may be considered to minimize the 
risk of nephrotoxicity.  Compared to the vancomycin AUC24h threshold of 600 mg*h/L that is 
currently recommended by the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring 
guideline, these thresholds had comparable PPVs but significantly higher sensitivities.  On the 
other hand, this study supports the continued use of the vancomycin AUC24h threshold of 600 
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